Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;12(Suppl 1):22-26.
doi: 10.1007/s11789-017-0090-3.

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)

P Grützmacher  1 , B Öhm  2 , S Szymczak  2 , C Dorbath  2 , M Brzoska  2 , C Kleinert  2
Affiliations
Review

Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)

P Grützmacher et al. Clin Res Cardiol Suppl. 2017 Mar.

Abstract

General lipoprotein (Lp) (a) screening can help to identify patients at high risk for cardiovascular disease. Non-invasive methods allow early detection of clinically asymptomatic incipient atherosclerotic disease. Medical treatment options are still unsatisfactory. Lp(a) apheresis is an established treatment in Germany for secondary prevention of progressive cardiovascular disease. Statin-based lowering of LDL cholesterol and thrombocyte aggregation inhibitors still represent the basis of medical treatment. Target levels for LDL-cholesterol should be modified in patients with hyperlipoproteinemia (a).

Keywords: Cardiovascular prevention; Lipoprotein (a); Lp (a) apheresis; Target LDL cholesterol.

PubMed Disclaimer

Conflict of interest statement

P. Grützmacher has received honoraria for lectures from Fresenius, B. Braun, Diamed, Kaneka, Amgen, Sanofi and MSD, B. Öhm, S. Szymczak, C. Dorbath, M. Brzoska and C. Kleinert declare that they have no competing interests.

References

    1. Ridker P, Hennekens C, Stampfer M. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993;270:2195–2199. doi: 10.1001/jama.1993.03510180065035. - DOI - PubMed
    1. Emerging Risk Factors Collaboration Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;303:412–423. - PMC - PubMed
    1. Nordestgaard B, Chapman M, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853. doi: 10.1093/eurheartj/ehq386. - DOI - PMC - PubMed
    1. Yusuf S, Lonn E, Pais P, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032–2043. doi: 10.1056/NEJMoa1600177. - DOI - PubMed
    1. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021–2031. doi: 10.1056/NEJMoa1600176. - DOI - PubMed